Protalix Biotherapeutics Inc (PLX) Stock Analysis
Verdict: HOLD
Profitable commercial transition and low P/E provide a floor, but lumpy milestone revenues make timing the next leg to $3.19 difficult.
Investment score: 64/100
Analysis as of
Is Protalix Biotherapeutics Inc stock worth reviewing? AI model thesis
The AI model identifies PLX as a rare profitable micro-cap biotech trading at a deep value discount (P/E 12x) relative to its R&D pipeline value. While cash flow is lumpy, the partnership with Pfizer and the commercial status of Elfabrio provide a safety net that many peers lack.
7-factor investment score
- Valuation: 85/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Protalix Biotherapeutics Inc opportunities and risks
What speaks for PLX
- Deep Valuation Discount vs Peers
What speaks against PLX
- Lumpy Milestone-Dependent Revenue
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PLX | 12.0x | 2.4x | 6.9x | 70.0% | 20.1% | 7.0% |
| KRRO | n/a | 36.3x | n/a | 73.2% | -2954.1% | -50.7% |
| IMUX | n/a | 0.0x | 0.4x | 0.0% | 0.0% | -55.8% |
| ABOS | n/a | 0.0x | n/a | 0.0% | 0.0% | -63.6% |
| TNXP | n/a | 11.2x | n/a | 52.6% | -839.5% | -67.4% |
| HUMA | n/a | 59.2x | n/a | -748.5% | -4840.8% | -85.8% |
| Peer median | n/a | 11.2x | n/a | 0.0% | -839.5% | -63.6% |
Frequently asked questions about Protalix Biotherapeutics Inc (PLX)
Is PLX stock a good investment?
The cached TradeMates AI model rates Protalix Biotherapeutics Inc as HOLD with an investment score of 64/100. The AI model identifies PLX as a rare profitable micro-cap biotech trading at a deep value discount (P/E 12x) relative to its R&D pipeline value. While cash flow is lumpy, the partnership with Pfizer and the commercial status of Elfabrio provide a safety net that many peers lack. This is algorithmic model output, not personal investment advice.
Is PLX stock a buy?
The TradeMates model verdict for PLX is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.